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The excitatory amino acid transporters (EAATs) are transmembrane proteins responsible for the uptake of
(S)-glutamate from the synaptic cleft. To date, five subtypes EAAT1−5 have been identified for which selective
inhibitors have been discovered for EAAT1 and EAAT2. By screening of a commercially available compound library
consisting of 4,000 compounds, N-acyl-N-phenylpiperazine analog (±)-exo-1 was identified to be a non-selective
inhibitor at EAAT1−3 displaying IC50 values in the mid-micromolar range (10 μM, 40 μM and 30 μM at EAAT1, 2 and
3, respectively). Subsequently, we designed and synthesized a series of analogs to explore the structure-activity-
relationship of this scaffold in the search for analogs characterized by increased inhibitory potency and/or EAAT
subtype selectivity. Despite extensive efforts, all analogs of (±)-exo-1 proved to be either inactive or to have least
3-fold lower inhibitory potency than the lead, and furthermore none of the active analogs displayed selectivity for a
particular subtype amongst the EAAT1−3. On the basis of our findings, we speculate that (±)-exo-1 binds to a
recess (deepening) on the EAAT proteins than a well-defined pocket.
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In the central nervous system (CNS), the excitatory amino
acid transporters (EAATs) are transmembrane proteins re-
sponsible for the uptake of (S)-glutamate (Glu) from the
synaptic cleft. Five subtypes have been identified, named
EAAT1–EAAT5 in humans and GLAST, GLT-1, EAAC1,
EAAT4 and EAAT5, respectively, in rodents. (Bunch et al.
2009) While EAAT5 is found exclusively in the retina, sub-
types EAAT1–4 are expressed differentially within the
CNS with respect to brain regions as well as at the cellular
level: EAAT1 and EAAT2 are expressed primarily on astro-
cytes, but EAAT2 is also found in neurons, astrocytes and
oligodendrocytes. (Lauriat et al. 2007) Subtype EAAT3 is* Correspondence: lebu@sund.ku.dk
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in any medium, provided the original work is pdistributed predominantly in postsynaptic neuronal sites,
(Nieoullon et al. 2006) whereas EAAT4 is distributed in
Purkinje cells as well as in the cerebral cortex. (Massie
et al. 2001) Discovery of subtype selective ligands for the
EAATs has attracted much attention over the past decade,
(Jensen et al. 2009) the latest being the disclosure of
UCPH-101 as first subtype selective EAAT1-inhibitor
(Figure 1). (Jensen et al. 2009; Erichsen et al. 2010; Huynh
et al. 2012,ab).
Results and discussion
From screening of a 4,000 compounds-library at HEK293
cells stably expressing human EAAT1−3 N-acyl-N-
phenylpiperazine analog (±)-exo-1 was identified as a non-
selective inhibitor at the transporter exhibiting IC50 values
in the mid-micromolar range (10 μM, 40 μM and 30 μM at
EAAT1, -2 and -3, respectively, Figure 2).n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Chemical structures of the EAAT1-selective inhibitor UCPH-101, (Jensen et al. 2009; Erichsen et al. 2010) and EAAT2-selective
inhibitors DHK, (Jensen & Bräuner-Osborne 2004) DPAG, (Sagot et al. 2008) and WAY-213613 (Dunlop et al. 2005).
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high-throughput screenings (HTS) and a frequent core
skeleton in marketed drugs, (Millan et al. 2001; Fragasso
et al. 2006; Weisberg et al. 2007) we were motivated to
explore the structure-activity-relationship (SAR) of this
new class of EAAT inhibitors. A conventional medicinal
chemistry analysis of (±)-exo-1 suggests that the amide
functionality, the aniline nitrogen, the phenyl ring and
the trifluoromethyl group may play key roles in binding of
this class of EAAT inhibitors. Consequently, the chemical
structure can be broken down into three fragments: a core
skeleton being the acyl-phenylpiperazine scaffold and two
substituents being the trifluoromethyl- and the bicyclo
[2.2.1]heptanyl group (Figure 1). The SAR study was
designed as to study the influence of one of the two substit-
uents (Figure 1) individually including the stereochemical
organization around the α-carbonyl carbon.
The SAR study commenced by investigation of the
influence of bicycle[2.2.1]heptanyl group on the EAAT
inhibitory activity. The stereochemical configuration of the
α-cabonyl carbon was addressed by the synthesis of endo-
conformer (±)-endo-1 (Table 1) from commercially available
(±)-endo-carboxylic acid and N-(3-trifluoromethylphenyl)-
piperazine 4, the latter prepared by a palladium-catalyzed
amination of commercially available piperazine (Scheme 1).
(Nishiyama et al. 1998) Furthermore, the racemic and
diastereomeric mixture (±)-endo-exo-1 was prepared
from the corresponding acid (±)-endo-exo-6 obtained fromFigure 2 Chemical structure of screening hit N-acyl-N-phenylpiperazin
mid-micromolar range (IC50 = 10, 40 and 30 μM, respectively).oxidation of commercially available (±)-endo-exo-bicyclo
[2.2.1]heptanylmethyl alcohol ((±)-endo-exo-5) (Scheme 2)
using KMnO4 and K2CO3 in H2O. Isolation of (±)-endo-
exo-6 turned out to be difficult for which reason it was
used directly in the next step. (Gudipati et al. 1993) To
search for the optimal bulkiness of the lipophilic sub-
stituent, larger as well as smaller rigid hydrophobic
ring-systems were introduced (2.1−2.5). Moreover,
analogs 2.6−2.10 comprising alkyl group of varying
length and bulkiness were designed to explore the effect of
increased flexibility of this substituent on ligand binding.
Furthermore, analogs 2.11–2.17 address if the bicyclo
[2.2.1]heptane could be substituted for an aromatic moiety,
whereas the analogs 2.18–2.21 were designed to explore
the distinct substitution for a hydrophobic group. The
synthesis of piperazine analogs 1 and 2.1−2.21 was carried
out by amidation of 4 using the respective carboxylic
acids, acid chlorides, benzenesulfonyl chloride and benzyl
carbonochloridate afforded the corresponding amides in
moderate to good yields (Scheme 1). The rationally
designed 3-trifluoromethylphenylpiperazine analogs were
supplemented by commercially available analogs 2.22–
2.31, as a quick way of expanding the SAR into the chem-
ical space beyond rational guidance. Finally, the importance
of the amide functionality was explored by the synthesis of
carbamate 2.32 by acylation of 4 with carbonochloridate,
sulfonamide 2.33 by treatment of 4 with phenylsulfonyl
chloride, amine 2.34 by reduction of (±)-endo-exo-1 withe (±)-exo-1 displaying inhibitory activity at EAAT1−3 in the
Table 1 Pharmacological characterization of piperazine analogs 1 and 2.1−2.40 as inhibitors at HEK293 cells stably
expressing human EAAT1-3 in the [3H]-D-aspartate uptake assay (Jensen & Bräuner-Osborne 2004)
R1 EAAT1 EAAT2 EAAT3
(±)-exo-1 10 [5.03 ± 0.12] 40 [4.44 ± 0.14] 30 [4.78 ± 0.10]
(±)-endo-1 14 [4.88 ± 0.09] 32 [4.52 ± 0.12] 10 [5.04 ± 0.13]
(±)-endo-exo-1 14 [4.87 ± 0.08] 42 [4.42 ± 0.11] 14 [4.94 ± 0.16]
2.1 >300 >300 >300
2.2 >300 >300 >300
2.3 ~100 ~100 ~100
2.4 >300 >300 >300
2.5 >300 >300 >300
2.6 >1000 >300 >300
2.7 >1000 >100 >100
2.8 >300 >300 >300
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Table 1 Pharmacological characterization of piperazine analogs 1 and 2.1−2.40 as inhibitors at HEK293 cells stably
expressing human EAAT1-3 in the [3H]-D-aspartate uptake assay (Jensen & Bräuner-Osborne 2004) (Continued)
2.9 >300 >300 >300
2.10 >300 >300 >300
2.11 ~150 >100 >100
2.12 >100 >100 >100
2.13 >300 >300 >300
2.14 >300 >300 >300
2.15 >300 >300 >300
2.16 >100 >100 >100
2.17 >300 >300 >1000
2.18 >300 >300 >300
2.19 >300 >300 >300
2.20 >300 >300 >300
2.21 >300 >300 >300
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Table 1 Pharmacological characterization of piperazine analogs 1 and 2.1−2.40 as inhibitors at HEK293 cells stably
expressing human EAAT1-3 in the [3H]-D-aspartate uptake assay (Jensen & Bräuner-Osborne 2004) (Continued)
2.22 ~100 >100 >100
2.23 >300 >300 >100
2.24 >100 >100 >100
2.25 >300 >100 >300
2.26 >300 >300 >300
2.27 >300 >300 >300
2.28 >300 >300 >300
2.29 >300 >100 >100
2.30 >300 >1000 >300
2.31 >100 >100 >100
2.32 >1000 >300 >300
2.33 >1000 >300 >1000
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Table 1 Pharmacological characterization of piperazine analogs 1 and 2.1−2.40 as inhibitors at HEK293 cells stably
expressing human EAAT1-3 in the [3H]-D-aspartate uptake assay (Jensen & Bräuner-Osborne 2004) (Continued)
(±)-endo-exo-2.34 >300 >300 >300
2.35 >300 >300 >1000
2.36 >300 >100 >300
2.37 >300 >100 >100
2.38 >300 >300 >300
2.39 >100 >100 >100
2.40 >500 >1000 >500
All values are given as IC50 in μM with pIC50 ± S.E.M. values in brackets (for the active analogs).
Scheme 1 Synthesis of phenylpiperazine 4 and analogs 1, 2.1−2.21 and 2.33−2.35 a. aReagents and conditions: (a) 3-Trifluoromethylphenylbromide,
Pd(OAc)2, P(
tBu)3, NaO
tBu, o-xylene, 120°C, 17 h, 77%. (b) Appropriate carboxylic acid, TBTU, DIPEA, dry DMF, rt, 20 h, 51−92%. (c) Appropriate acid chloride
(except for the synthesis of 2.32: benzyl carbonochloridate), Et3N, dry dichloromethane, rt, 30 min, 71−78%. (d) Benzenesulfonyl chloride, Et3N, dry
dichloromethane, rt, 30 min, 71%. (e) BnBr, Et3N, dry dichloromethane, rt, 24 h, 57%. (f) Starting from (±)-endo-exo-1: LiAlH4, THF, rt, 72 h, 71%.
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Scheme 2 Synthesis of piperazine analog (±)-endo-exo-3.2 a. a Reagents and conditions: (a) KMnO4, K2CO3, H2O, rt, 17 h. (b) Piperazine,
DIPEA, TBTU, DMF, rt, 24 h, 49%. (c) 1-Bromo-4-(trifluoromethyl)benzene, Pd(OAc)2, P(
tBu)3, NaO
tBu, dry o-xylene, 120°C, 24 h, 56%.
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alkylation of phenylpiperazine 4. (Burkhard et al. 2010) In
addition, these analogs were supplemented by five commer-
cially available structurally diverse analogs 2.36–2.40.
We then turned to the design of analogs for investigation
of the influence on EAAT inhibitory activity of the chemical
nature of the trifluoromethyl group as well as its position
on the phenyl ring. A series of 12 analogs were included in
the SAR study, all wherein the (±)-endo-exo-bicyclic
[2.2.1]-acyl group was conserved (analogs 3.1−3.12,
Table 2): Simplification of the chemical structure by
depletion of the trifluoromethyl group provides analog
(±)-endo-exo-3.1, while shifting the 3-trifluoromethyl
group to the 4- or 2-positions affords analogs (±)-endo-
exo-3.2 and (±)-endo-exo-3.5, respectively (Table 2 and
Scheme 2). The latter two analogs were supplemented by
commercially available analogs (±)-endo-exo-3.3, (±)-endo-
exo-3.4 and (±)-endo-exo-3.6. Continuing the design stage,
substitution of the 3-trifluoromethyl group for a chloride,
hydroxyl-, cyano- and methoxy group, provides analogs
(±)-endo-exo-3.7−3.10 respectively (Table 2), whereas
2,4-difluorophenyl analog (±)-endo-exo-3.11 was included
due to readily available starting materials. Analog (±)-endo-
exo-3.12 could be obtained from commercial suppliers
and thus included with the notion that it comprises an
N-diphenylmethyl group, which is indeed chemically
distinct from the N-3-trifluoromethylphenyl group and
furthermore the connecting nitrogen will be protonated
at physiological pH=7.4. The analogs were synthesized
starting from the appropriate phenylpiperazine and
(±)-endo-exo-6 under standard coupling conditions
(TBTU, DIPEA in DMF) for the amide formation to
afford the target compounds in moderate yields (Scheme 3)
(Balalaie et al. 2007).
Pharmacological characterization
In total, 54 piperazine analogs 2.1−2.40 and 3.1−3.12
were characterized pharmacologically at stable HEK293
cells expressing human EAAT1−3 in a [3H]-D-aspartate
uptake assay, (Jensen & Bräuner-Osborne 2004) and
the results are summarized in Table 1 and Table 2. The
endo-isomer 1 (endo-isomer) displayed inhibitory activities
at EAAT1−3 comparable with those of the exo-isomer 1
(lead structure) (IC50 = 14 μM, 32 μM and 10 μM vs.10 μM, 40 μM and 30 μM, respectively). In line with
this, endo-exo 1, which is a 1:1 ratio of endo/exo moiety
displayed IC50 values at EAAT1−3 of IC50 = 14 μM, 42 μM
and 14 μM, respectively. Usually, such findings would lead
to the conclusion that the bicyclo-[2.2.1]-heptanyl group
occupies a promiscuous hydrophobic pocket, which
could be optimized for increased potency. However,
upon increasing or decreasing the hydrophobic bulk
and/or flexibility, a clear drop in potency was observed
(analogs 2.1−2.17, Table 1). Except for analogs 2.3 and
2.11, which displayed only a 5−15 fold drop in inhibitory
potency across the subtypes, all of these analogs would be
characterized as inactive (IC50 >100 μM or >300 μM,
Table 1). These findings could open up for the hypothesis
that the pocket is indeed not hydrophobic but instead
hydrophilic in nature. Upon binding of the hydrophobic
alkane group, water molecules are forced out and ligand
binding is entropically driven rather than enthalpically.
Thus analogs 2.18−2.31, which comprise a hydrophobic
group, could be potential inhibitors. However, none of
these displayed any inhibitory activity at EAAT1−3
(IC50 >100, >300 or >1000 μM, Table 1). Continuing
the characterization, neither the carbamate 2.32 nor
the sulfonamide 2.33 analog displayed inhibitory activity
at EAAT1−3, and likewise all amines 2.34−2.40 were
found to be inactive at all three subtypes.
The pharmacological results for the twelve analogs
3.1−3.12, which address the influence of substituent 2
(Figure 2) on inhibitory activity at EAAT1−3 are sum-
marized in Table 2. While it was not surprising that
removal or repositioning of the 3-trifluoromethyl group
(analog 3.1, 3.2 and 3.5, respectively) resulted in loss of
inhibitory activity, the further nine analogs 3.3, 3.4,
3.6−3.12 were also inactive or displayed at least a 3-fold
lower inhibitory activity than (±)-exo-1.
Conclusion
In conclusion, screening of a compound library identified
(±)-exo-1 as a broad range EAAT1−3 inhibitor exhibiting
IC50 values at the three transporters in the mid-micromolar
range. Subsequently, rational design and synthesis of 33
analogs of (±)-exo-1 was carried out, together with the
purchase of 21 analogs. Thus, a total of 54 piperazine
analogs were characterized pharmacologically as inhibitors
Table 2 Pharmacological characterization of analogs 3.1–3.12 as inhibitors at HEK293 cells stably expressing human
EAAT1−3 in the [1H]-D-aspartate uptake assay (Jensen & Bräuner-Osborne 2004)
R2 EAAT1 EAAT2 EAAT3
(±)-endo-exo-3.1 >300 >300 >300
(±)-endo-exo-3.2 >300 >300 >300
(±)-endo-exo-3.3 >100 >100 >100
(±)-endo-exo-3.4 >100 ~100 >300
(±)-endo-exo-3.5 ~300 >300 >300
(±)-endo-exo-3.6 >100 ~100 >100
(±)-endo-exo-3.7 ~300 ~300 >300
(±)-endo-exo-3.8 >300 >300 >300
(±)-endo-exo-3.9 >300 >300 >300
(±)-endo-exo-3.10 >300 >300 >300
(±)-endo-exo-3.11 >300 >300 >300
(±)-endo-exo-3n12 >100 ~100 >100
All values are given as IC50 in μM with pIC50 ± S.E.M. values in brackets (for the active analogs).
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(±)-endo-exo-3.1 : R = H
(±)-endo-exo-3.5 : R = 2-F3C-
(±)-endo-exo-3.7 : R = 2-Cl-
(±)-endo-exo-3.8 : R = 3-HO-
(±)-endo-exo-3.9 : R = 2-NC-
(±)-endo-exo-3.10: R = 3-MeO-




Scheme 3 Synthesis of piperazine analogs 3.1, 3.5, 3.8−3.11 by use of the coupling reagent TBTU a. a Reagents and conditions: (a) TBTU,
DIPEA, dry DMF, rt, 20 h, 40−58%.
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displayed inhibitory potency in the mid-micromolar range
comparable to that of the lead structure (±)-exo-1. The
remaining analogs were inactive or at least three fold
weaker inhibitors at EAAT1−3 than the lead, none of them
displaying signs of subtype-selectivity. Given the structural
diversity of the analogs characterized pharmacologically,
we speculate if the lead structure (±)-exo-1 adheres to a re-
cess (deepening) in the surface of the protein rather than
binds in an organized way to a well-defined pocket.
Experimental section
All commercially available reagents were used without
further purification. THF was distilled over sodium/ben-
zophenone, Et2O was dried over neatly cut sodium and
dichloromethane was dried over 3 Å molecular sieves.
All solvents were tested for water content using a Karl
Fisher apparatus. All reactions involving dry solvents or
sensitive agents were performed under a nitrogen atmos-
phere, and glassware was dried prior to use. All reactions
were monitored by analytical thin-layer chromatography
(TLC, Merck silica gel 60 F254 aluminum sheets). Flash
chromatography was carried out using Merck silica gel
60A (35−70 micron). 1H NMR spectra were recorded on a
300 MHz Varian Mercury 300BB or a 400 MHz Avance
Bruker and 13C NMR spectra on a 75 MHz Varian Gemini
2000BB or a 100 MHz Avance Bruker. Preparative HPLC
was done using Agilent Prep HPLC systems with Agilent
1100 series pump, Agilent 1200 series diode array, multiple
wavelength detector (G1365B), and Agilent PrepHT High
Performance Preparative Cartridge Column (Zorbax, 300
SB-C18 Prep HT, 21.2 × 250 mm, 7 μm). LC-MS spectra
were recorded using an Agilent 1200 series solvent delivery
system equipped with an autoinjector coupled to an Agilent
6400 series triple quadrupole mass spectrometer equipped
with an electrospray ionization source. Gradients of 5%
aqueous MeCN + 0.05% HCOOH (eluent A), and 95%
aqueous MeCN + 0.043% formic acid (eluent B) were
employed. Melting points were measured using a MPA 100
Optimelt automatic melting point system and are stateduncorrected. Compounds were dry either under high
vacuum or freeze dried using a Holm & Halby, Heto
LyoPro 6000 freezedrier.
General procedure a: synthesis of amides using
O-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium
tetrafluoroborate (TBTU) as coupling reagent
To a suspension of the appropriate phenylpiperazine
analog (0.33 mmol), the carboxylic acid (0.40 mmol) and
TBTU (0.43 mmol) in dry DMF (4 mL) under an N2
atmosphere, was added DIPEA (1.32 mmol) and reaction
mixture was stirred for 20 h at rt. The reaction mixture
was quenched with brine (5 mL) and extracted with
dichloromethane (3 × 20 mL). The combined organic
phases were washed with H2O (20 mL) and brine (20 mL)
and dried over anhydrous Na2SO4. After concentration
in vacuo, the crude product was purified by column
chromatography on silica gel in accordance with details
described for the analog.
General procedure B: synthesis of amides using acid chlorides
To a suspension of 1-(3-(trifluoromethyl)phenyl)piperazine
(4) (0.33 mmol) in dry dichloromethane (5 mL) at 0°C
under a N2 atmosphere was added Et3N (0.91 mmol). The
reaction mixture was stirred for 10 min at 0°C, then the
appropriate acid chloride (0.48 mmol) was added and
stirring continued for 30 minutes at rt. The reaction mix-
ture was quenched with sat. NH4Cl (5 mL) and extracted
with dichloromethane (3 × 20 mL). The combined organic
phases were washed with H2O (20 mL) and brine (20 mL)
and dried over Na2SO4. After concentration in vacuo,
the crude product was purified by column chromatog-





(4) and commercially available (±)-endo-bicyclo[2.2.1]
heptane-2-carboxylic acid by general procedure A in
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http://www.springerplus.com/content/2/1/11261% yield as a pale-yellow oil. Rf 0.25 (heptane/EtOAc
3:1). 1H NMR (300 MHz, CDCl3) δ 7.36 (t, J = 8.4 Hz,
1H), 7.12−7.04 (m, 3H), 3.94−3.89 (m, 1H), 3.79−3.62
(m, 3H), 3.30−3.08 (m, 4H), 2.95 (dt, J = 10.8, 4.2 Hz,
1H), 2.40 (br s, 1H), 2.29 (br s, 1H), 1.95 (ddd, J = 12.0,
4.5, 2.4 Hz, 1H), 1.64−1.28 (m, 7H). 13C NMR (75 MHz,
CDCl3) δ 172.3, 151.1, 131.5 (q, J = 31.5 Hz), 129.7,
124.2 (q, J = 270.7 Hz), 119.3, 116.5 (q, J = 3.8 Hz),
112.6 (q, J = 3.8 Hz), 49.5, 45.2, 43.7, 41.7, 40.8, 40.5,
40.2, 37.1, 32.2, 29.1, 21.1. LC-MS (m/z) calcd for
C19H23F3N2O [M+H
+], 353.2; found, 353.2. Anal. calcd
for C19H23F3N2O × 1HCl: C 58.69, H 6.22, N 7.20 found





acid ((±)-endo-exo-(6)) by general procedure A in 36%
yield as a pale-yellow oil. Rf 0.50 (heptane/EtOAc 1:1).
1H NMR (300 MHz, CDCl3) δ 7.38−7.33 (m, 1H),
7.12−7.02 (m, 3H), 3.98−3.96 (m, 1H), 3.75 (br s, 2H),
3.67 (br s, 2H), 3.21 (br s, 4H), 2.98−2.92 (m, 0.6H),
2.40 (br s, 1.4H), 2.29 (br s, 1H), 1.95−1.92 (m, 1H),
1.62−1.25 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 173.1,
151.3, 131.5 (q, J = 31.5 Hz), 129.7, 124.2 (q, J = 270.7 Hz),
119.2, 116.5 (q, J = 3.8 Hz), 112.7 (q, J = 3.8 Hz), 50.2,
49.8, 45.2, 43.7, 41.7, 40.8, 40.4, 36.7, 32.3, 28.9, 21.9.
LC-MS (m/z) calcd for C19H23F3N2O [M+H
+], 353.2;
found, 353.4. HPLC: purity254 > 99%.
Bicyclo[2.2.2]octan-2-yl(4-(3-(trifluoromethyl)phenyl)
piperazin-1-yl)methanone (2.1)
Obtained from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
and racemic (±)-endo-exo-bicyclo[2.2.2]octane-2-carbox-
ylic acid ((±)-endo-exo-(6)) by general procedure A in 59%
yield as a pale-yellow oil. Rf 0.95 (1:1 heptane/EtOAc).
1H
NMR (400 MHz, CDCl3) δ 7.12 (t, J = 6.0 Hz, 1H), 6.50
(dd, J = 6.0, 1.0 Hz, 1H), 6.42−6.35 (m, 2H), 3.82 (br s,
2H), 3.64 (br s, 2H), 3.32 (br s, 4H), 2.79−2.76 (m, 1H),
2.19−2.16 (m, 1H), 1.79−1.73 (m, 1H), 1.69−1.18 (m,
10H). 13C NMR (100 MHz, CDCl3) δ 174.0, 151.2, 131.5
(q, J = 31.5 Hz), 129.7, 125.6 (q, J = 270.7 Hz), 119.3, 116.5
(q, J = 3.8 Hz), 112.6 (q, J = 3.8 Hz), 49.2, 45.2, 41.6, 38.8,
28.4, 27.6, 26.5, 25.3, 25.2, 23.9, 21.5. LC-MS (m/z) calcd
for C20H25F3N2O [M+H




Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
and 1-adamantanecarboxylic acid by general procedure A
in 73% yield as a pale-yellow oil. Rf 0.68 (100% EtOAc).
1H
NMR (300 MHz, CDCl3) δ 7.39−7.32 (m, 1H), 7.12−7.04(m, 3H), 3.87 (dd, J = 6.0, 3.0 Hz, 4H), 3.21 (dd, J = 6.0, 3.0
Hz, 4H), 2.06−2.03 (m, 9H), 1.70−1.77 (m, 6H). 13C NMR
(75 MHz, CDCl3) δ 176.2, 151.5, 131.1 (q, J = 31.5 Hz),
130.1, 127.2 (q, J = 270.8 Hz), 119.4, 116.9 (q, J = 3.8 Hz),
112.8 (q, J = 3.8 Hz), 55.2, 49.7, 49.6, 45.4, 43.9,
42.1, 39.5, 37.1, 28.9, 19.1. LC-MS (m/z) calcd for
C22H27F3N2O [M+H
+], 393.2; found, 393.2. Anal. calcd
for C22H27F3N2O × 1HCl: C 61.61, H 6.58, N 6.53 found




(4) and cyclohexanecarboxylic acid by general procedure
A in 59% yield as a yellow oil. Rf 0.15 (heptane/EtOAc 3:1).
1H NMR (300 MHz, CDCl3) δ 7.35 (t, J = 7.8 Hz, 1H),
7.12−7.03 (m, 3H), 3.78 (br s, 2H), 3.67 (br s, 2H), 3.21
(br s, 4H), 2.50 (tt, J = 11.4, 3.3 Hz, 1H), 1.83−1.69
(m, 5H), 1.55 (dq, J = 11.4, 3.9 Hz, 2H), 1.35−1.23
(m, 3H). 13C NMR (75 MHz, CDCl3) δ 175.0, 151.5,
131.9 (q, J = 31.5 Hz), 130.1, 124.6 (q, J = 270.8 Hz) 119.7
(q, J = 1.5 Hz), 117.0 (q, J = 3.8 Hz), 113.0 (q, J = 3.8 Hz),
49.8, 49.5, 45.1, 40.9, 29.8, 26.3. LC-MS (m/z) calcd for
C18H23F3N2O [M+H
+], 341.1; found, 341.1. Anal. calcd
for C18H23F3N3O × 1HCl: C 57.37, H 6.42, N 7.43 found
C 57.38, H 6.20, N 7.38.
Cyclopentyl(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
methanone (2.4)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
and cyclopentanecarbonyl chloride by general procedure
B in 85% yield as a yellow oil. Rf 0.50 (heptane/EtOAc
1:1). 1H NMR (400 MHz, CDCl3) δ 7.37 (t, J = 8.0 Hz,
1H), 7.13−7.06 (m, 3H), 3.80 (dd, J = 8.0, 4.0 Hz, 2H), 3.70
(dd, J = 8.0, 4.0 Hz, 2H), 3.24 (dd, J = 8.0, 4.0 Hz, 2H ),
3.19 (dd, J = 8.0, 4.0 Hz, 2H), 1.92−1.54 (m, 9H). 13C NMR
(100 MHz, CDCl3) δ 176.1, 147.0, 134.2 (q, J = 31.5 Hz),
132.4, 125.0 (q, J = 270.7 Hz), 124.9, 118.1 (q, J = 3.8 Hz),
117.6 (q, J = 3.8 Hz), 54.7, 43.1, 42.4, 31.6, 27.5. LC-MS
(m/z) calcd for C17H21F3N2O [M+H
+], 327.2; found, 327.2.
HPLC: purity254 > 97%.
Cyclopropyl(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
methanone (2.5)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
and cyclopropanecarboxylic acid by general procedure A
in 51% yield as a yellow oil. Rf 0.55 (100% EtOAc).
1H
NMR (300 MHz, CDCl3) δ 7.39−7.32 (m, 1H), 7.12−7.05
(m, 3H), 3.83 (br s, 4H), 3.26 (br s, 2H), 3.24 (br s, 2H),
1.78 (m, 1H), 1.05−1.00 (m, 2H), 0.84−0.78 (m, 2H). 13C
NMR (75 MHz, CDCl3) δ 172.5, 151.5, 131.9 (q, J = 31.5
Hz), 130.1, 127.5 (q, J = 270.8 Hz), 119.6 (q, J = 0.8 Hz),
116.9 (q, J = 3.8 Hz), 113.0 (q, J = 3.8 Hz), 49.5, 49.3, 45.6,
42.2, 11.4, 8.0. LC-MS (m/z) calcd for C15H17F3N2O
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(4) and pivaloyl chloride by general procedure B in 78%
yield as a clear oil. Rf 0.28 (heptane/EtOAc 3:1).
1H NMR
(300 MHz, CDCl3) δ 7.35 (dt, J = 8.1, 0.9 Hz, 1H),
7.11−7.03 (m, 3H), 3.81 (dd, J = 5.1, 5.1 Hz, 4H), 3.21
(dd, J = 5.1, 5.1 Hz, 4H), 1.32 (s, 9H). 13C NMR (75 MHz,
CDCl3) δ 176.4, 151.1, 131.5 (q, J = 31.5 Hz), 129.7, 124.2
(q, J = 270.8 Hz), 119.1 (q, J = 1.5 Hz), 116.5 (q, J = 3.8
Hz), 112.4 (q, J = 3.8 Hz), 49.0, 44.8, 38.7, 28.4. LC-MS
(m/z) calcd for C16H21F3N2O [M+H
+], 315.2; found,
315.2. Anal. calcd for C16H21F3N2O × 1HCl: C 55.11, H
6.21, N 7.96 found C 54.78, H 6.32, N 7.99.
1-(4-(3-(Trifluoromethyl)phenyl)piperazin-1-yl)ethanone (2.7)
Obtained from 1-(3-(trifluoromethyl)phenyl)piperazine
(4) and acetic acid by general procedure A in 64% yield
as a yellow oil. Rf 0.22 (100% EtOAc).
1H NMR (300
MHz, CDCl3) δ 7.36 (t, J = 9.0 Hz, 1H), 7.13−7.04 (m, 3H),
3.78 (dd, J = 6.0, 3.0 Hz, 2H), 3.64 (dd, J = 6.0, 3.0 Hz, 2H),
3.24 (dd, J = 6.0, 3.0 Hz, 2H), 3.20(dd, J = 6.0, 3.0 Hz, 2H),
2.15 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 169.4, 151.4,
131.9 (q, J = 31.5 Hz), 130.1, 124.6 (q, J = 270.8 Hz), 119.7
(q, J = 1.5 Hz), 117.1 (q, J = 3.8 Hz), 113.1 (q, J = 3.8 Hz),
49.5, 49.3, 46.4, 41.6, 21.8. LC-MS (m/z) calcd for
C13H15F3N2O [M+H
+], 273.1; found, 273.1. Anal. calcd for
C13H15F3N2O × 1HCl: C 50.58, H 5.22, N 9.07 found C




(4) and isovaleryl chloride by general procedure B in
59% yield as a pale-yellow oil. Rf 0.40 (heptane/EtOAc 1:1).
1H NMR (400 MHz, CDCl3) δ 7.39 (t, J = 6.9 Hz, 1H),
7.16−7.10 (m, 3H), 3.82 (dd, J = 6.0, 3.0 Hz, 2H), 3.68
(dd, J = 6.0, 4.0 Hz, 2H), 3.23 (br s, 4H), 2.27 (d, J = 4.0
Hz, 2H), 2.17 (septet, J = 6.0 Hz, 1H), 1.00 (d, J = 6.0 Hz,
6H). 13C NMR (100 MHz, CDCl3) δ 173.7, 147.8, 133.4
(q, J = 31.5 Hz), 132.1, 123.9, 123.6 (q, J = 270.8 Hz),
117.1 (q, J = 3.8 Hz), 113.4 (q, J = 3.8 Hz), 47.8, 42.6,
41.3, 27.0, 22.9. LC-MS (m/z) calcd for C16H21F3N2O




(4) and 3,3-dimethylbutanoyl chloride by general procedure
B in 73% yield as a pale-orange oil. Rf 0.50 (heptane/EtOAc 1:1). 1H NMR (400 MHz, CDCl3) δ 7.39−7.35
(m, 1H), 7.14−7.11 (m, 2H), 7.08−7.06 (m, 1H), 3.81
(dd, J = 8.0, 4.0 Hz, 2H), 3.69 (dd, J = 8.0, 4.0 Hz, 2H),
3.22 (dd, J = 8.0, 4.0 Hz, 2H), 3.21 (dd, J = 8.0, 4.0 Hz,
2H), 2.31 (s, 2H), 1.08 (s, 9H). 13C NMR (100 MHz,
CDCl3) δ 171.9, 147.3, 134.2 (q, J = 31.5 Hz), 132.3,
126.2, 124.7 (q, J = 270.8 Hz), 123.4 (q, J = 3.8 Hz),
117.4 (q, J = 3.8 Hz), 54.5, 46.1, 33.0, 31.5, 21.1. LC-MS
(m/z) calcd for C17H23F3N2O [M+H
+], 329.2; found,




(4) and 4-methylvaleryl chloride by general procedure B
in 87% yield as a clear oil. Rf 0.35 (heptane/EtOAc 1:1).
1H NMR (400 MHz, CDCl3) δ 7.37 (t, J = 6.0 Hz, 1H),
7.14−7.07 (m, 3H), 3.79 (dd, J = 8.0, 4.0 Hz, 2H), 3.65
(dd, J = 8.0, 4.0 Hz, 2H), 3.24 (dd, J = 8.0, 4.0 Hz, 2H),
3.22 (dd, J = 8.0, 4.0 Hz, 2H), 2.35 (dd, J = 6.0, 6.0 Hz, 2H),
1.63−1.52 (m, 3H), 0.93 (d, J = 3.0 Hz, 6H). 13C NMR (100
MHz, CDCl3) δ 172.1, 151.1, 131.6 (q, J = 31.5 Hz), 129.7,
124.2 (q, J = 271.0 Hz), 119.3, 116.6 (q, J = 4.0 Hz), 112.7
(q, J = 4.0 Hz), 49.2, 49.0, 45.4, 41.3, 34.2, 31.3, 27.9, 22.7,
22.4. LC-MS (m/z) calcd for C17H23F3N2O [M+H
+], 329.2;




(4) and benzoic acid by general procedure A in 58% yield
as a pale-yellow oil. Rf 0.33 (heptane/EtOAc 2:3).
1H NMR
(300 MHz, CDCl3) δ 7.47−7.39 (m, 6H), 7.26−7.20 (m, 2H),
7.10 (d, J = 7.5 Hz, 1H), 3.75 (br s, 2H), 3.48 (br s, 2H),
3.28 (br s, 4H). 13C NMR (75 MHz, CDCl3) δ 170.8, 151.5,
135.8, 132.1 (q, J = 31.5 Hz), 130.3 (d, J = 1.5 Hz), 130.1
(d, J = 1.5 Hz), 129.0, 127.5, 124.6 (q, J = 267.0 Hz),
119.9, 117.2, 113.3, 49.7, 47.8. LC-MS (m/z) calcd for
C18H17F3N2O [M+H
+], 335.1; found, 335.1. Anal. calcd
for C18H17F3N2O × 1HCl: C 58.30, H 4.89, N 7.55




(4) and benzo[d][1,3]dioxole-5-carboxylic acid by general
procedure A in 60% yield as a white solid. Rf 0.18
(heptane/EtOAc 3:1). 1H NMR (300 MHz, CDCl3) δ
7.36 (t, J = 9.0 Hz, 1H), 7.13−7.05 (m, 3H), 6.97−6.82
(m, 3H), 6.00 (s, 2H), 3.77 (br s, 4H), 3.24 (br s, 4H).
13C NMR (75 MHz, CDCl3) δ 169.9, 151.0, 149.0, 147.7,
131.5 (q, J = 31.5 Hz), 129.7, 128.9, 124.1 (q, J = 270.8 Hz),
121.7, 119.4, 116.8 (q, J = 3.8 Hz), 112.8 (q, J = 3.8 Hz),
108.2, 108.1, 101.5, 49.2, 42.8; mp 87−89°C. LC-MS (m/z)
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+], 379.1; found, 379.1.
Anal. calcd for C19H17F3N2O3: C 60.32, H 4.53, N 7.40
found C 59.95, H 4.40, N 7.02.(3-Phenoxyphenyl)(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
methanone (2.13)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine
(4) and 3-phenoxybenzoic acid by general procedure A in
62 % yield as a pale-yellow oil. Rf 0.20 (heptane/EtOAc 3:1).
1H NMR (300 MHz, CDCl3) δ 7.40−7.22 (m, 5H),
7.16−6.99 (m, 8H), 3.90 (br s, 2H), 3.60 (br s, 2H), 3.25
(br s, 2H), 3.16 (br s, 2H). 13C NMR (75 MHz, CDCl3) δ
170.1, 158.1, 156.7, 151.4, 137.4, 132.0 (q, J = 31.5 Hz), 130.6,
130.4, 130.1, 124.6 (q, J = 270.8 Hz), 124.4, 121.9, 120.2,
119.9, 119.6, 117.3 (q, J = 3.8 Hz), 113.3 (q, J = 3.8 Hz), 49.7,
42.9. LC-MS (m/z) calcd for C24H21F3N2O2 [M+H
+], 427.1;
found, 427.1. Anal. calcd for C24H21F3N3O2 × 1HCl: C
62.27, H 4.79, N 6.05 found C 63.52, H 4.64, N 5.90.1-Phenylcyclopentyl-(4-(3-(trifluoromethyl)phenyl)
piperazin-1-yl)methanone (2.14)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine
(4) and 1-phenylcyclopentanecarboxylic acid by general
procedure A in 92 % yield as an off-white solid. Rf 0.37
(heptane/EtOAc 3:1). 1H NMR (300 MHz, CDCl3) δ
7.40−7.17 (m, 8H), 7.05 (d, J = 6.0 Hz, 1H), 3,78 (br s,
4H), 3.25 (br s, 2H), 3.13 (br s, 2H), 2.70−2.41 (m, 4H),
2.06−1.87 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 175.2,
151.4, 145.8, 143.2, 131.9 (q, J = 31.5 Hz), 130.0, 128.7,
127.5, 126.8, 124.6 (q, J = 270.8 Hz) 119.4 (q, J = 1.5 Hz),
116.8 (q, J = 3.8 Hz), 112.9 (q, J = 3.8 Hz), 59.3, 58.9, 48.7,
38.8, 36.4, 25.7, 24.0; mp 77−79°C. LC-MS (m/z) calcd for
C23H25F3N2O [M+H
+], 403.2; found, 403.2. Anal. calcd
for C23H25F3N2O: C 68.64, H 6.26, N 6.96 found C 70.90,
H 6.37, N 6.73.Naphthalen-1-yl(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
methanone (2.15)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine
(4) and 1-naphthoic acid by general procedure A in
83% yield as a colorless oil. Rf 0.19 (heptane/EtOAc 3:1).
1H NMR (300 MHz, CDCl3) δ 7.90−7.83 (m, 3H),
7.55−7.32 (m, 5H), 7.12−7.02 (m, 3H), 4.21−4.01 (m, 2H),
3.42−3.35 (m, 4H), 3.11−2.99 (m, 2H). 13C NMR
(75 MHz, CDCl3) δ 169.9, 151.4, 134.1, 133.9, 132.0
(q, J = 31.5 Hz), 130.1, 129.8, 128.9, 127.6, 127.0, 125.6,
125.1, 124.5 (q, J = 270.8 Hz), 124.3, 119.4 (q, J = 1.5 Hz),
117.3 (q, J = 3.8 Hz), 113.3 (q, J = 3.8 Hz), 50.1, 49.7, 47.3,
42.0. LC-MS (m/z) calcd for C22H19F3N2O [M+H
+],
385.1; found, 385.1. Anal. calcd for C22H19F3N2O ×
1HCl: C 62.79, H 4.79, N 6.66 found C 64.82, H 4.72,
N 6.26.Thiophen-2-yl(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
methanone (2.16)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
and thiophene-2-carboxylic acid by general procedure A
in 69% yield as a pale-yellow oil. Rf 0.68 (100% EtOAc).
1H NMR (300 MHz, CDCl3) δ 7.46 (dd, J = 6.0, 3.0
Hz, 1H), 7.39−7.32 (m, 2H), 7.13−7.04 (m, 4H), 3.92
(dd, J = 6.0, 3.0 Hz, 4H), 3.28 (dd, J = 6.0, 3.0 Hz, 4H).
13C NMR (75 MHz, CDCl3) δ 164.1, 151.4, 137.1, 131.9
(q, J = 31.5 Hz), 130.1, 129.5, 129.3, 127.2, 124.6
(q, J = 270.8 Hz), 119.7 (q, J = 1.5 Hz), 117.2 (q, J = 3.8 Hz),
113.1 (q, J = 3.8 Hz), 49.5, 45.7. LC-MS (m/z) calcd for
C16H15F3N2OS [M+H
+], 341.0; found, 341.0. Anal. calcd
for C16H15F3N2OS ×1HCl: C 51.00, H 4.28, N 7.43 found




(4) and 2-phenylacetyl chloride by general procedure B
in 77% yield as a clear oil. Rf 0.28 (heptane/EtOAc 1:1).
1H NMR (300 MHz, CDCl3) δ 7.34−7.20 (m, 6H),
7.09−6.96 (m, 3H), 3.79 (dd, J = 6.0, 3.0 Hz, 2H), 3.78
(s, 2H), 3.58 (dd, J = 6.0, 3.0 Hz, 2H), 3.16 (dd, J = 6.0, 3.0
Hz, 2H), 2.99 (dd, J = 6.0, 3.0 Hz, 2H). 13C NMR (75 MHz,
CDCl3) δ 169.8, 151.3, 137.8, 131.3 (q, J = 31.5 Hz), 129.4,
129.1, 128.3, 127.1, 124.3 (q, J = 270.8 Hz), 118.6 (d, J = 0.8
Hz), 115.6 (q, J = 3.8 Hz), 112.0 (q, J = 3.8 Hz), 62.9, 52.8,
48.6. LC-MS (m/z) calcd for C19H19F3N2O [M+H
+], 349.1;
found, 349.1. Anal. Calcd for C19H19F3N2O × 1HCl: C
60.20, H 5.16, N 7.12 found C 59.30, H 5.24, N 7.28.
4-Aminophenyl-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
methanone (2.18)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
(103 mg, 0.37 mmol) and 4-((tert-butoxycarbonyl)amino)
benzoic acid in accordance with general procedure A to
provide N-Boc-2.18 in 48% yield as a brown oil. Rf 0.44
(heptane/EtOAc 1:1). 1H NMR (400 MHz, MeOD) δ
7.37−7.27 (m, 5H), 7.07−6.99 (m, 3H), 3.81−3.61 (m, 4H),
3.27−3.07 (m, 4H), 1.46 (s, 9H). 13C NMR (100 MHz,
MeOD) δ 170.3, 152.5, 151.1, 140.1, 131.8, 131.5, 129.7,
128.5, 127.5, 125.6, 119.4, 118.1, 116.8, 114.1, 112.9
(d, J = 4.0 Hz), 81.1, 49.2, 31.9, 29.0, 28.3, 22.7. LC-MS
(m/z) calcd for C23H26F3N3O3 [M+H
+], 450.1, found, 450.1.
The intermediate product N-Boc-2.18 was dissolved in
DCM (2 mL) and TFA (2 mL) and stirred for 1h at rt. The
reaction mixture was evaporated and the title compound
2.18 was obtained in 69% yield as TFA-salt. 1H NMR (400
MHz, MeOD) δ 7.43−7.39 (m, 1H), 7.35−7.32 (m, 2H),
7.23−7.20 (m, 2H), 7.12−7.10 (m, 1H), 6.90−6.87 (m, 2H),
3.79 (s, 4H), 3.30−3.26 (m, 4H). 13C NMR (100 MHz,
MeOD) δ 173.1, 152.1, 148.3, 132.8, 132.5 (q, J = 8.0 Hz),
131.0, 130.4, 127.2, 126.7, 124.5, 120.8, 118.6, 117.2
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49.7. LC-MS (m/z) calcd for C18H18F3N3O [M+H
+], 350.1;
found, 350.1. HPLC: purity254 >97%.
3-Aminophenyl-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
methanone (2.19)
Prepared from 3-trifluoromethylphenylpiperazine (4)
(101 mg, 0.37 mmol) and 3-((tert-butoxycarbonyl)amino)
benzoic acid by general procedure A in 85% yield as a
reddish oil. Rf 0.42 (heptane/EtOAc 1:1).
1H NMR
(400 MHz, MeOD) δ 7.45 (s, 1H), 7.36−7.23 (p, J = 8.0
Hz, 3H), 7.06−6.98 (m, 4 H), 6.78 (s, 1H), 3.95−3.75
(m, 2H), 3.66−3.46 (m, 2H), 3.27−3.01 (m, 4H), 1.45
(s, 9H). 13C NMR (100 MHz, MeOD) δ 172.4, 155.2,
152.9, 141.1 (q, J = 2.0 Hz), 137.2, 132.6 (q, J = 4.0 Hz),
131.0, 130.3, 129.8, 127.2, 124.8, 122.0, 120.9 (q, J = 2.0
Hz), 118.0, 117.3, 113.7, 81.2, 79.5, 54.8, 30.7, 28.7, 24.3,
23.8. LC-MS (m/z) calcd for C23H26F3N3O3 [M+H
+],
450.1, found, 450.1. The intermediate product N-Boc-2.19
was dissolved in DCM (2 mL) and TFA (2 mL) and stirred
for 1h at rt. The reaction mixture was evaporated to afford
the title compound in 99% yield as TFA-salt. 1H NMR
(400 MHz, MeOD) δ 7.67−7.62 (m, 2H), 7.57−7.49
(m, 3H), 7.44−7.40 (m, 1H), 7.24−7.22 (m, 2H), 7.14−7.12
(m, 1H), 4.01−3.80 (m, 2H), 3.74−3.50 (m, 2H), 3.45−3.18
(m, 4H). 13C NMR (100 MHz, MeOD) δ 170.8, 159.0
(q, J = 10.5 Hz), 152.7, 138.6, 134.6, 134.24, 133.5,
132.5 (q, J = 8.0 Hz), 131.7, 131.5, 131.01, 130.6, 128.5,
127.5, 127.2, 125.0, 124.9, 124.5, 122.3, 120.9 (d, J = 1.0
Hz), 117.4 (q, J = 1.0 Hz), 114.7, 113.7 (q, J = 1.0 Hz), 54.5,
54.2. LC-MS (m/z) calcd for C18H18F3N3O [M+H
+], 350.1;
found, 350.1. HPLC: purity254 >96%.
2-Amino-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
ethanone (2.20)
Prepared from (4) (104 mg, 0.37 mmol) and N-Boc-
glycine-OH (105 mg, 0.36 mmol) by general procedure
A to provide N-Boc-2.20 in 86% yield as a colorless
oil. Rf 0.25 (heptane/EtOAc 1:1).
1H NMR (400 MHz,
MeOD) δ 7.41 (t, J = 8.0 Hz, 1H), 7.23−7.20 (m, 2H),
7.11 (d, J = 8.0 Hz, 1H), 3.97 (s, 2H), 3.75 (s, 2H), 3.66
(s, 2H), 3.28−3.23 (m, 4H), 1.45 (s, 9H). The inter-
mediate N-Boc-2.20 was dissolved in DCM (2 mL)
and TFA (2 mL) and stirred for 30 min at rt. The reaction
mixture was evaporated to afford the title compound as
the TFA-salt in quantitative yield. 1H NMR (400 MHz,
MeOD) δ 7.45−7.40 (m, 1H), 7.24−7.21 (m, 2H), 7.14−7.12
(m, 1H), 4.00 (s, 2H), 3.80 (t, J = 4.0 Hz, 2H), 3.62 (t, J = 4.0
Hz, 2H), 3.30−3.26 (m, 2H). 13C NMR (100 MHz, MeOD)
δ 165.7, 159.9 (q, J = 41.0 Hz), 152.7, 132.40 (t, 32.0 Hz),
131.0, 127.2, 124.5, 120.9, 117.5, 114.7, 113.6 (q, J = 4.0 Hz),
49.9, 49.7, 45.5, 43.1, 41.0, 27.7. LC-MS (m/z) calcd
for C13H16F3N3O [M+H
+], 288.1; found, 288.1. HPLC:
purity254 >99%.2-Amino-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)
ethanone (2.21)
Prepared from (16) (103 mg, 0.37 mmol) and N-Boc-
glycine-OH (69 mg, 0.36 mmol) by general procedure A to
provide N-Boc-2.21 in 51% yield as a colorless oil. Rf 0.18
(heptane/EtOAc 1:1). The intermediate N-Boc-2.20 was
dissolved in DCM (2 mL) and TFA (2 mL) and stirred for
45 min at rt. The reaction mixture was evaporated to afford
the title compound as the TFA-salt in quantitative yield. 1H
NMR (400 MHz, MeOD) δ 7.44−7.40 (m, 1H), 7.24−7.20
(m, 2H), 7.12 (dt, J = 8.0 Hz, 1H), 3.78 (t, J = 4.0 Hz, 2H),
3.68 (t, J = 4.0, 2H), 3.26−3.21 (m, 6H), 2.83 (t, J = 4.0 Hz,
2H). 13C NMR (100 MHz, MeOD) δ 170.4, 152.8, 132.7,
132.4, 131.0, 127.2, 120.8, 117.5, 117.3 (q, J = 4.0 Hz), 113.5
(q, J = 4.0 Hz), 54.4, 50.0, 46.16, 42.65. LC-MS (m/z) calcd
for C14H18F3N3O [M+H




Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
and benzyl carbonochloridate by general procedure B in
73% yield as a clear oil. Rf 0.43 (heptane/EtOAc 3:1).
1H
NMR (300 MHz, CDCl3) δ 7.36−7.29 (m, 6H), 7.10−7.01
(m, 3H), 5.15 (s, 2H), 3.66 (dd, J = 6.0, 3.0 Hz, 4H), 3.17
(br s, 4H). 13C NMR (75 MHz, CDCl3) δ 155.1, 151.2,
136.5, 131.3 (q, J = 31.5 Hz), 129.6, 128.5, 128.1, 127.9,
124.2 (q, J = 270.8 Hz), 119.4 (q, J = 1.5 Hz), 116.5
(q, J = 3.8 Hz), 112.4 (q, J = 3.8 Hz), 67.3, 48.9, 43.5. LC-MS
(m/z) calcd for C19H19F3N2O2 [M+H
+], 365.1; found, 365.1.
Anal. Calcd for C19H19F3N2O2 × 1HCl: C 57.35, H 5.03, N
6.91 found C 56.93, H 5.03, N 6.99.
1-(Phenylsulfonyl)-4-(3-(trifluoromethyl)phenyl)piperazine
(2.33)
Prepared from 1-(3-(trifluoromethyl)phenyl)piperazine (4)
and benzenesulfonyl chloride by general procedure B in
71% yield as a white solid. Rf 0.39 (heptane/EtOAc 3:1).
1H
NMR (300 MHz, CDCl3) δ 7.80−7.76 (m, 2H), 7.65−7.51
(m, 3H), 7.32 (t, J = 7.5 Hz, 1H), 7.11−6.97 (m, 3H),
3.30−3.26 (m, 4H), 3.19−3.16 (m, 4H). 13C NMR (75 MHz,
CDCl3) δ 151.1, 135.6, 133.5, 131.9 (q, J = 31.5 Hz), 130.2,
129.6, 128.2, 124.5 (q, J = 270.8 Hz), 119.9 (q, J = 1.5 Hz),
117.4 (q, J = 3.8 Hz), 113.5 (q, J = 3.8 Hz), 49.1, 46.4;
mp 109−111°C (decomposed). LC-MS (m/z) calcd for
C17H17F3N2O2S [M+H
+], 371.1; found, 371.1. Anal.
Calcd for C17H17F3N2O2S: C 55.13, H 4.63, N 7.56
found C 54.60, H 4.44, N 7.41.
(±)-endo-exo-Bicyclo[2.2.1]heptan-2-ylmethyl)-4-
(3-(trifluoromethyl)phenyl)piperazine (2.34)
A solution of (±)-endo-exo-bicyclo[2.2.1]heptan-2-yl
(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methanone
((±)-endo-exo 2.3) (116.5 mg, 0.30 mmol) in dry THF
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mg, 0.33 mmol) in THF (5 mL) at 0°C under a N2
atmosphere. The reaction mixture was stirred for 3 days
at rt, quenched with 2N NaOH (2 mL) and extracted with
dichloromethane (3 × 25 mL). The combined organic
phases were washed with H2O (20 mL) and brine (20 mL).
The organic phase was dried over anhydrous Na2SO4.
After concentration in vacuo, the crude product was
purified by column chromatography on silica gel to afford
the titled compound as a pale-yellow oil (72 mg, 0.21
mmol, 71% yield): Rf 0.42 (heptane/EtOAc 2:1).
1H NMR
(400 MHz, CDCl3) δ 7.37 (t, J = 8.0 Hz, 1H), 7.13−7.00
(m, 3H), 3.91−3.66 (m, 4H), 3.25−3.16 (m, 4H), 2.97−2.41
(m, 2H), 2.32−2.28 (m, 1H), 1.98−1.92 (m, 1H), 1.62−1.19
(m, 9H). 13C NMR (100 MHz, CDCl3) δ 151.2, 130.1
(q, J = 31.5 Hz), 130.2, 124.5 (q, J = 270.7 Hz), 119.3
(d, J = 3.8 Hz), 117.3 (q, J = 3.8 Hz), 113.2 (q, J = 3.8 Hz),
49.0, 44.3, 40.9, 40.4, 37.2, 36.7, 36.0, 34.9, 32.2, 29.5, 28.9,
24.5. LC-MS (m/z) calcd for C19H25F3N2 [M+H
+], 339.2;
found, 339.2. HPLC: purity254 > 99%.
1-Benzyl-4-(3-(trifluoromethyl)phenyl)piperazine (2.35)
BnBr (54 μL, 0.46 mmol) was added dropwise to a solution
of 1-(3-(trifluoromethyl)phenyl)piperazine (4) (100 mg, 0.43
mmol) and Et3N (126 μL, 0.46 mmol) in dichloromethane
(5 mL) at rt under a N2 atmosphere. The reaction mixture
was stirred for 24 hours, quenched with saturated NH4Cl
(5 mL) and extracted with dichloromethane (3 × 20 mL).
The combined organic phases were washed with H2O
(20 mL) and brine (20 mL). The organic phase was dried
over anhydrous Na2SO4. After concentration in vacuo,
the crude product was purified by column chromatog-
raphy on silica gel to afford the titled compound as a
clear oil (79 mg, 0.25 mmol, 57% yield): Rf 0.41 (heptane/
EtOAc 2:1). 1H NMR (300 MHz, CDCl3) δ 7.34−7.19
(m, 6H), 7.08−6.99 (m, 3H), 3.55 (br s, 2H), 3.21 (dd,
J = 6.0, 6.0 Hz, 4H), 2.59 (dd, J = 6.0, 6.0 Hz, 4H). 13C
NMR (75 MHz, CDCl3) δ 151.3, 135.2, 131.7 (q, J = 31.5
Hz), 130.1, 129.3, 128.9, 127.4 124.6 (q, J = 270.8 Hz),
119.6 (d, J = 3.8 Hz), 117.0 (q, J = 3.8 Hz), 113.0 (q,
J = 3.8 Hz), 49.3, 49.1, 46.2, 41.9, 41.5. LC-MS (m/z)
calcd for C18H19F3N2 [M+H
+], 321.2; found, 321.2.
Anal. Calcd for C18H19F3N2 × 1HCl: C 60.59, H 5.65,
N 7.85 found C 55.74, H 5.23, N 7.12.
Bicyclo[2.2.1]heptan-2-yl(4-phenylpiperazin-1-yl)
methanone (3.1)
Prepared in accordance with general procedure A. The
crude product was purified by flash chromatography to
afford 3.1 as a clear oil (240 mg, 43%). Rf 0.20 (heptane/
EtOAc 3:1). 1H NMR (400 MHz, CDCl3 ) δ 7.31−7.25
(m, 2H), 6.95−6.85 (m, 3H), 3.99−3.61 (m, 4H), 3.30−3.03
(m, 4H), 2.98−2.91 (m, 0.5H), 2.44−2.39 (m, 1.5H),
2.34−2.26 (m, 1H), 1.99−1.90 (m, 1H), 1.64−1.16 (m, 7H).13C NMR (100 MHz, CDCl3) δ 173.9, 172.2, 151.0, 129.2,
120.5, 120.5, 116.6, 50.2, 49.8, 49.7, 49.6, 45.4, 45.3, 44.2,
43.7, 41.9, 41.7, 40.8, 40.6, 40.4, 37.2, 36.7, 36.0, 34.9, 32.2,
29. 5, 28.9, 28.9, 24.5. LC-MS (m/z) calcd for C18H24N2O
[M+H+], 285.1; found, 285.1. HPLC: purity254 >95%.
(±)-endo-exo-Bicyclo[2.2.1]heptan-2-yl(4-(4-(trifluoromethyl)
phenyl)piperazin-1-yl)methanone (3.2)
Pd(OAc)2 (1.0 mg, 4.6 μmol) and P(
tBu)3 (1.0 M in
toluene, 16 μL, 0.016 mmol) were added to a solution
of 4-(bicyclo[2.2.1]heptane-2-carbonyl)piperazin-1-ium
chloride (±)-endo-exo-7 (101 mg, 0.41 mmol), 1-bromo-4-
(trifluoromethyl)benzene (63 μL, 0.45 mmol) and NaOtBu
(86 mg, 0.90 mmol) in dry o-xylene (1.3 mL) at rt under a
N2 atmosphere. The reaction mixture was stirred at 120°C
for 24 hours, quenched with H2O (10 mL) and extracted
with EtOAc (3 × 20 mL). The combined organic phases
were washed with H2O (20 mL) and brine (20 mL). The
organic phase was dried over anhydrous Na2SO4. After
concentration in vacuo, the crude product was purified by
column chromatography on silica gel to afford the titled
compound as a white solid (80 mg, 0.23 mmol, 56%): Rf
0.25 (heptane/EtOAc 3:1). 1H NMR (400 MHz, CDCl3) δ
7.42 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 3.90−3.80
(m, 0.5H), 3.75−3.62 (m, 4H), 3.31−3.08 (m, 4H), 2.91−2.80
(m, 0.5H), 2.40−2.30 (m, 1H), 2.28−2.19 (m, 1H), 1.91−1.82
(m, 1H), 1.60−1.10 (m, 7H). 13C NMR (100 MHz, CDCl3)
δ 174.0, 172.3, 153.0, 126.6, 126.5, 126.4, 126.4, 125.9,
123.2, 121.4, 121.1, 114.9, 48.8, 48.4, 48.3, 48.2, 45.1, 44.9,
44.2, 43.7, 41.6, 41.4, 40.8, 40.3, 37.1, 36.7, 36.0, 34.9, 32.2,
29.5, 28.9, 28.9, 24.5; mp: 126−127°C (decomposed).
LC-MS (m/z) calcd for C19H23F3N2O [M+H
+], 353.2;
found, 353.2. HPLC: purity254 > 95%.
(±)-endo-exo-Bicyclo[2.2.1]heptan-2-yl(4-(2-(trifluoromethyl)
phenyl)piperazin-1- yl)methanone ((±)-endo-exo-3.5)
Prepared in accordance with general procedure A. The
crude product was purified twice by flash chromatography
to afford (±)-endo-exo-3.5 as a clear oil (48 mg, 14%). Rf
0.32 (heptane/EtOAc 3:1). 1H NMR (400 MHz, CDCl3 ) δ
7.64 (d, J = 7.86 Hz, 1H), 7.52 (t, J = 7.69 Hz, 1H), 7.31 (d,
J = 8.02 Hz, 1H), 7.28−7.22 (m, 1H), 3.72 (s, 4H), 2.99−2.85
(m, 4.5H), 2.45−2.36 (m, 1.5H) 2.33−2.25 (m, 1H), 2.00−1.90
(m, 1H), 1.65−1.15 (m, 7H). 13C NMR (100 MHz, CDCl3) δ
173.9, 172.3, 151.8, 132.8, 127.6, 127.3, 127.2, 125.2, 124.0,
122.6, 54.1, 53.8, 53.3, 53.2, 46.0, 45.9, 44.2, 43.7, 42.4, 42.2,
40.8, 40.6, 40.3, 37.2, 36.7, 36.0, 34.9, 32.2, 29.4, 28.9, 28.9,
24.5. LC-MS (m/z) calcd for C19H23F3N2O [M+H
+], 353.1;
found, 353.1. HPLC: purity254 > 95%.
(±)-endo-exo-Bicyclo[2.2.1]heptan-2-yl(4-(3-chlorophenyl)
piperazin-1-yl)methanone ((±)-endo-exo-3.7)
Prepared in accordance with general procedure A. The
crude product was purified by flash chromatography to
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EtOAc 3:1). 1H NMR (400 MHz, CDCl3 ) δ 7.17 (t, J = 8.09
Hz, 1H), 6.87 (t, J = 2.04 Hz, 1H), 6.85 (d, J = 7.84 Hz, 1H)
6.78 (dd, J = 8.35, 2.15 Hz, 1H), 3.95−3.60 (m, 4H),
3.25−3.05(m, 4H), 2.97−2.90 (m, 0.5H), 2.45−2.37 (m, 1.5H),
2.33−2.25 (m, 1H) 1.98−1.88 (m, 1H), 1.64−1.06 (m, 7H).
13C NMR (100 MHz, CDCl3) δ 173.8, 172.1, 151.9, 134.9,
130.0, 119.9, 116.2, 114.3, 49.4, 49.1, 48.9, 45.1, 44.9, 44.9,
43.6, 41.5, 41.3, 40.7, 40.5, 40.2, 37.0, 36.6, 35.9, 34.8, 32.0,
29.3, 28.7, 24.4. LC-MS (m/z) calcd for C18H23ClN2O




carboxylic acid ((±)-endo-exo-6) and 3-(piperazin-1-yl)phe-
nol by general procedure A in 40% yield as a white solid. Rf
0.45 (heptane/EtOAc 2:1). 1H NMR (400 MHz, CDCl3) δ
7.13 (t, J = 8.0 Hz, 1H), 6.52−6.36 (m, 3H), 3.93−3.64
(m, 4H), 3.22−2.92 (m, 4H), 2.45−2.41 (m, 1H), 2.31−2.28
(m, 1H), 1.97−1.88 (m, 1H), 1.63−1.18 (m, 8H). 13C NMR
(100 MHz, CDCl3) δ 173.5, 157.4, 152.3, 130.1, 108.7,
107.7, 103.6, 50.2, 49.8, 49.1, 45.3, 44.3, 43.7, 41.8,
40.6, 40.5, 37.2, 36.8, 36.0, 35.1, 32.2, 29.5, 28.9, 28.9,
24.5; mp: 187−189°C (decomposed). LC-MS (m/z) calcd
for C18H24N2O2 [M+H




Prepared in accordance with general procedure A. The
crude product was purified by flash chromatography to
afford 3.9 as a clear oil (63 mg, 63%). Rf 0.15 (heptane/
EtOAc 3:1). 1H NMR (400 MHz, CDCl3 ) δ 7.37−7.31
(m, 1H), 7.15−7.10 (m, 3H), 3.98−3.62 (m, 4H), 3.30−3.10
(m, 4H), 2.98−2.90 (m, 0.5H), 2.46−2.36 (m, 1.5H),
2.34−2.26 (m, 1H), 1.98−1.88 (m, 1H), 1.64−1.10 (m, 7H).
13C NMR (100 MHz, CDCl3) δ 173.9, 172.3, 151.0, 130.0,
123.3, 120.4, 119.1, 118.9, 113.2, 49.1, 48.8, 48.6, 45.0,
44.9, 44.2, 43.7, 41.5, 41.3, 40.8, 40.6, 40.3, 37.1, 36.7,
36.0, 34.9, 32.2, 29.4, 28.9, 28.8, 24.5. LC-MS (m/z)
calcd for C19H23N3O [M+H





carboxylic acid ((±)-endo-exo-6) and 1-(3-methoxyphenyl)
piperazine by general procedure A in 45% yield as a clear
oil. Rf 0.35 (heptane/EtOAc 2:1).
1H NMR (400 MHz,
CDCl3) δ 7.19 (t, J = 8.0 Hz, 1H), 6.55−6.44 (m, 3H),
3.92−3.61 (m, 4H), 3.48 (s, 3H), 3.24−2.92 (m, 4H),
2.44−2.40 (m, 1H), 2.31−2.27 (m, 1H), 1.97−1.89 (m, 1H),
1.61−1.17 (m, 8H). 13C NMR (100 MHz, CDCl3) δ 173.2,160.7, 152.4, 129.9, 109.3, 105.1, 103.1, 55.2, 50.8, 50.0,
49.6, 49.6, 49.4, 45.4, 45.3, 44.3, 43.8, 41.9, 41.7, 40.8, 40.6,
40.4, 37.2, 36.8, 36.0, 34.9, 32.2, 29.5, 29.0, 28.9, 27.0, 24.5.
LC-MS (m/z) calcd for C19H26N2O2 [M+H
+], 315.2;




carboxylic acid ((±)-endo-exo-6) and 1-(2,4-difluorophenyl)
piperazine by general procedure A. After chromatography
(Rf = 0.43, heptane/EtOAc 2:1). The title compound was
isolated in 58% yield as a clear oil. 1H NMR (400 MHz,
CDCl3) δ 6.92−6.77 (m, 3H), 3.93−3.64 (m, 4H), 3.07−2.90
(m, 4H), 2.44−2.27 (m, 2H), 1.98−1.90 (m, 1H), 1.62−1.17
(m, 8H). 13C NMR (100 MHz, CDCl3) δ 173.9, 172.3, 159.5
(d, J = 12.0 Hz), 157.0 (d, J = 12.0 Hz), 154.6 (d, J = 12.0
Hz), 136.4 (d, J = 4.0 Hz), 136.2 (d, J = 4.0 Hz), 129.0, 128.4,
126.9, 119.9 (q, J = 4.0 Hz), 110.9 (d, J = 2.0 Hz), 110.7
(d, J = 2.0 Hz), 105.1, 104.9 (d, 2.0 Hz), 104.6, 53.4, 51.8,
51.4, 51.0, 45.7, 45.6, 44.2, 43.2, 42.0, 41.8, 40.8, 40.6,
40.4, 37.2, 36.8, 36.0, 29.0, 28.9, 24.6. LC-MS (m/z) calcd
for C18H22F2N2O [M+H
+], 321.2; found, 321.2. HPLC:
purity254 > 97%.
1-(3-(Trifluoromethyl)phenyl)piperazine (4)
Piperazine (5.74 g, 66.6 mmol), 3-bromobenzotrifluoride
(5.0 g, 22.2 mmol), Pd(OAc)2 (50 mg, 220 μmol), P(
tBu)3
(216 μL, 880 μmol) and NaOtBu (3 g, 31.1 mmol) were
stirred in dry o-xylene (50 mL) at 120ºC under a N2
atmosphere for 17 h. H2O (25 mL) was added and the
crude reaction was extracted with EtOAc (3 × 50 mL)
and the combined organic phases were washed with
H2O (30 mL) and brine (30 mL). The organic phase was
dried over anhydrous Na2SO4. After concentration in
vacuo, the crude product was purified by column
chromatography on silica gel. This afforded the titled
compound (3.91 g, 17.0 mmol, 77%) as a yellow oil: Rf
0.23 (Et2O/MeCN/MeOH/Et3N 10:1:1:0.5).
1H NMR
(300 MHz, CDCl3) δ 7.33 (t, J = 7.95 Hz, 1H), 7.10−7.03
(m, 3H), 3.18 (dd, J = 9.0, 5.4 Hz, 4H), 3.04 (dd, J = 6.9, 5.1
Hz, 4H), 2.0 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 152.2,
131.9 (q, J = 30.8 Hz), 129.9, 124.7 (q, J = 271.5 Hz), 119.1
(q, J = 1.5 Hz), 116.2 (q, J = 3.8 Hz), 112.5 (q, J = 4.5 Hz),
50.1, 46.3. LC-MS (m/z) calcd for C11H13F3N2 [M+H
+],
231.1; found, 231.1. HPLC: purity254 > 95%.
(±)-endo-exo-Bicyclo[2.2.1]heptane-2-carboxylic acid
((±)-endo-exo-6)
A solution of KMnO4 (53.2 g, 336.5 mmol) in H2O
(190 mL) was added dropwise to a solution of bicyclo
[2.2.1]heptan-2-ylmethanol (17.0 g, 134.6 mmol) and
K2CO3 (7.4 g, 53.8 mmol) in H2O (380 mL) at 0°C and
stirred at room temperature for 24 hours. The crude
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extracted with EtOAc (3 × 1000 mL). The combined
organic phases were washed with H2O (500 mL), brine
(250 mL) and dried over anhydrous MgSO4. After
concentration in vacuo, the crude product was directly
used for the next step without purification.
(±)-endo-exo-Bicyclo[2.2.1]heptan-2-yl(piperazin-1-yl)
methanone ((±)-endo-exo-7)
DIPEA (2.8 g, 21.4 mmol) was added dropwise to a stirred
solution of (±)-endo-exo-bicyclo[2.2.1]heptane-2-carboxylic
acid ((±)-endo-exo-7) (1 g, 7.1 mmol) and piperazine
(1.85 g, 21.4 mmol) in dry DMF (60 mL) at 0°C under a
N2 atmosphere. A solution of TBTU (2.98 g, 9.27 mmol)
in DMF (26 mL) was added to the reaction mixture and
stirred at 0°C for 30 min. After 20 hours at rt, the reaction
mixture was quenched with brine (30 mL) and extracted
with dichloromethane (3 × 100mL). The combined organic
phases were washed with H2O (3 × 200 mL) and brine
(100 mL). The organic phase was dried over anhydrous
Na2SO4. After concentration in vacuo, the crude product
was purified by column chromatography on silica gel
(Et2O/MeOH/MeCN/Et3N 8:2:2:0.5). This afforded the title
compound as a pale-yellow oil (0.73 mg, 3.5 mmol, 49%
yield). The pure product was dissolved in dichloromethane
(40 mL) and 4N HCl in dioxane (0.88 mL, 3.5 mmol)
was added. The solution was evaporated to afford the
corresponding HCl salt. 1H NMR (300 MHz, CDCl3) δ
10.10 (br s, 2H), 4.10−3.80 (m, 4H), 3.22 (br s, 4H),
2.95−2.83 (m, 0.5H), 2.40−2.27 (m, 2.5H), 1.97−1.80
(m, 1H), 1.70−1.16 (m, 6H). 13C NMR (75 MHz,
CDCl3) δ 173.8, 172.2, 45.9, 45.4, 45.2, 45.0, 44.9, 44.8,
44.0, 43.5, 41.2, 41.1, 40.7, 40.4, 40.1, 37.0, 36.6, 35.8,
34.7, 32.0, 29.3, 28.7, 24.4, 8.7.
Analogs 2.22−2.31, 2.36−2.40, 3.3, 3.4, 3.6 and 3.12
were obtained as 5 mg portions pre-dissolved in DMSO
from ChemBridge corporation and used directly in the
[3H]-Asp-uptake assay.
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